An Investment holding with an offshore permit exposure

BPH Energy Limited (ASX:BPH) is a company holding investments in resources and medical technology. It owns a 36% interest in Advent Energy Ltd, an unlisted oil and gas explorer, and commercialises Australian biomedical technologies arising from collaborations with universities, medical institutes and hospitals.

PEP 11 in the headlines

The company's recent ASX announcements are dominated by updates on PEP 11, an offshore petroleum exploration permit. Titled PEP 11 Update, they were lodged on 12 June, 19 June, 3 July and 14 July 2026, with a Trading halt requested on 17 June 2026. On 12 June BPH, through its investee Asset Energy Pty Limited, participated in a Federal Court matter, and the 19 June update refers to the Federal Court dismissing an application. The reason for the trading halt has not been stated.

These are legal and regulatory events affecting an unlisted investee's permit, not drilling results or reserves. BPH has not been shown to have a proved resource or production Revenue in the material reviewed.

Funding and dilution

BPH lodged a quarterly Appendix 4C on 30 April 2026 for the March quarter, and a December 2025 quarterly on 28 January 2026. The cash and cash-flow figures could not be read for this draft, so none are given.

In early 2026 the company ran an Options placement. It proposed an issue of up to 622,428,284 listed options at an exercise price of A$0.03, expiring twelve months after issue, targeted for 30 January 2026. The options offer closed on 3 February 2026, with Quotation applications on 16 February. If all had been exercised the proceeds would be about A$18.7 million, but at a share price far below that strike, exercise looks unlikely unless the price rises; that is interpretation, not company guidance. A 58,000,000-share issue to director David Breeze on 11 February 2026 was made as director remuneration. Mr Breeze is recorded as holding 69,750,805 shares (5.73%).

Medtech and the wider context

Alongside oil and gas, BPH has biomedical interests, which gives it a mixed exposure to a volatile energy-permit process and to early-stage health technology. Both are capital-hungry and slow, and revenue from either has not been demonstrated in the sources reviewed. Investors should also note that an investment-holding company's value depends on unlisted holdings that are hard to value independently.

Upcoming milestones

An interim report is expected around 16 February 2027, though the date has not been confirmed by the company.